Intravesical Seeding of Upper Urinary Tract Urothelial Carcinoma Cells During Nephroureterectomy: An Exploratory Analysis from the THPMG Trial
Authors:
Open Access
- 4 September 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 43 (11) , 1139-1144
Abstract
The Pirarubicin Monotherapy Study Group trial was a randomized Phase II study that evaluated the efficacy of intravesical instillation of pirarubicin in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. This study conducted further analysis of the Pirarubicin Monotherapy Study Group cohort, focusing on intravesical seeding of cancer cells. Using the data from the Pirarubicin Monotherapy Study Group trial, bladder recurrence-free survival rates and factors associated with bladder recurrence in the control group were analyzed. Of 36 patients in the control group, 14 with positive urine cytology had more frequent recurrence when compared with the 22 patients with negative cytology (P = 0.004). Based on the multivariate analysis in the control group, voided urine cytology was an independent predictive factor of bladder recurrence (hazard ratio, 5.54; 95% confidence interval 1.12–27.5; P = 0.036). Of 72 patients in the Pirarubicin Monotherapy Study Group trial, 31 had positive urine cytology. Among the 31 patients, 17 patients who received pirarubicin instillation had fewer recurrences when compared with 14 patients who received control treatment (P = 0.0001). On multivariate analysis, pirarubicin instillation was an independent predictor of better recurrence-free survival rates in the patients with positive urine cytology (hazard ratio, 0.02; 95% confidence interval, 0.00–0.53; P = 0.018). Of 21 patients with bladder recurrence, 17 had recurrent tumor around cystotomy or in the bladder neck compromised by the urethral catheter, supporting the notion that tumor cells seeded in the injured urothelium. Intravesical instillation of pirarubicin immediately after nephroureterectomy significantly reduced the bladder recurrence rate in patients with positive voided urine cytology. The results suggest that intravesical seeding of upper urinary tract urothelial carcinoma occurs during nephroureterectomy.Keywords
This publication has 22 references indexed in Scilit:
- Prevention of Bladder Tumours after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: A Prospective, Multicentre, Randomised Clinical Trial of a Single Postoperative Intravesical Dose of Mitomycin C (the ODMIT-C Trial)European Urology, 2011
- Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: A single institutional retrospective long‐term follow‐up studyInternational Journal of Urology, 2010
- Primary urothelial carcinoma of the upper tract: Important clinicopathological factors predicting bladder recurrence after surgical resectionPathology International, 2009
- Multifocal Urothelial Cancers With the Mutator Phenotype are of Monoclonal Origin and Require Panurothelial Treatment for Tumor ClearanceJournal of Urology, 2006
- Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tractUrology, 2005
- BLADDER CANCER AS A PROGNOSTIC FACTOR FOR UPPER TRACT TRANSITIONAL CELL CARCINOMAJournal of Urology, 2004
- Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studiesInternational Journal of Cancer, 2002
- DISTINCT MICROSATELLITE ALTERATIONS IN UPPER URINARY TRACT TUMORS AND SUBSEQUENT BLADDER TUMORSJournal of Urology, 2001
- Metachronous multifocal development of urothelial cancers by intraluminal seedingThe Lancet, 1993
- Bladder Cancer — Field versus Clonal OriginNew England Journal of Medicine, 1992